Leaflet MONIYOT-131 14.8-3700MBq oral solution for therapeutic use
Indicated for: thyroid disorders; radioiodine therapy
Route of administration: oral
Substance: sodium iodide (131I) (thyroid hormone)
ATC: V10XA01 (Various | Other therapeutic radiopharmaceuticals | Iodine (131i) compounds)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Sodium iodide (131I) is a radioactive compound used in the treatment and diagnosis of thyroid conditions such as hyperthyroidism and thyroid cancer. It emits radiation that destroys overactive or cancerous thyroid cells.
It is administered orally, in capsule or solution form, and is quickly absorbed by the thyroid gland. Treatment with Sodium iodide (131I) is effective and minimally invasive, serving as an alternative to surgical interventions.
Side effects may include dry mouth, fatigue, or inflammation of the salivary glands. As a radioactive compound, its use requires special precautions to minimize radiation exposure.
Consult your doctor to discuss the benefits and risks of treatment with Sodium iodide (131I). It is important to follow all instructions to ensure the safety and effectiveness of the treatment.
General data about MONIYOT-131 14.8-3700MBq
- Substance: sodium iodide (131I)
- Date of last drug list: 01-03-2026
- Commercial code: W71714001
- Concentration: 14.8-3700MBq
- Pharmaceutical form: oral solution for therapeutic use
- Quantity: 1
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for sodium iodide (131I)
Concentrations available for sodium iodide (131I)
- 0.333 MBq - 3.7 MBq
- 0.37-3.7GBq
- 0.37-36MBq
- 14.8-3700MBq
- 3.7MBq
- 3.7MBq.1.85MBq.0.925MBq
- 37-5500MBq
- 37-7400MBq
- 37MBq-5.55GBq
- 38-7400MBq
- 50- 7400MBq